Sanctuary Advisors LLC Increases Holdings in IDEXX Laboratories, Inc. $IDXX

Sanctuary Advisors LLC increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,364 shares of the company’s stock after purchasing an additional 1,628 shares during the quarter. Sanctuary Advisors LLC’s holdings in IDEXX Laboratories were worth $8,071,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of IDXX. SHP Wealth Management purchased a new stake in shares of IDEXX Laboratories in the 4th quarter worth $26,000. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter worth $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at $29,000. WealthCollab LLC purchased a new position in shares of IDEXX Laboratories during the second quarter valued at $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of IDEXX Laboratories in the third quarter valued at about $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 1.5%

Shares of IDEXX Laboratories stock opened at $567.44 on Friday. The firm’s 50 day moving average price is $554.49 and its 200-day moving average price is $599.94. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 52-week low of $513.02 and a 52-week high of $769.98. The company has a market cap of $44.76 billion, a P/E ratio of 41.78, a PEG ratio of 3.15 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IDXX. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. UBS Group reduced their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.